A Randomized, Double‑Blind Clinical Assessment of the Effect of Low‑Dose Nicotinic Acid on Hyperphosphatemia in Patients with ESRD.
A Randomized, Double‑Blind Clinical Assessment of the Effect of Low‑Dose Nicotinic Acid on Hyperphosphatemia in Patients with ESRD.
Abstract:Aim: The aim of the present study was to assess the effect of low‑dose nicotinic acid on hyperphosphatemia inpatients with ESRD.Methods: In this randomized, double‑blind clinical trial, 100 dialysis patients referred to the Department ofNephrology, Patna Medical College and Hospital, Patna, Bihar, India for the period of six months wereevaluated.Results: The difference in mean age between niacin and placebo groups was not significant. At the end of thefirst month, the difference between two groups in calcium level was significant. At the end of the second month,the difference between the two groups in terms of phosphorus and calcium levels was significant. At the end ofthe third month, mean phosphorus level was significantly different between the two groups.Conclusion: We concluded that niacin (100 mg/day) decreased phosphorus serum level and increased HDLserum level in patients on dialysis
Abstract:Aim: The aim of the present study was to assess the effect of low‑dose nicotinic acid on hyperphosphatemia inpatients with ESRD.Methods: In this randomized, double‑blind clinical trial, 100 dialysis patients referred to the Department ofNephrology, Patna Medical College and Hospital, Patna, Bihar, India for the period of six months wereevaluated.Results: The difference in mean age between niacin and placebo groups was not significant. At the end of thefirst month, the difference between two groups in calcium level was significant. At the end of the second month,the difference between the two groups in terms of phosphorus and calcium levels was significant. At the end ofthe third month, mean phosphorus level was significantly different between the two groups.Conclusion: We concluded that niacin (100 mg/day) decreased phosphorus serum level and increased HDLserum level in patients on dialysis
End Stage Renal Disease, High‑Density Lipoprotein, Hyperphosphatemia, Nicotinic Acid.
End Stage Renal Disease, High‑Density Lipoprotein, Hyperphosphatemia, Nicotinic Acid.
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!